Lp(a)CCELERATE: Impact of Implementation Strategies on Lp(a) Testing
Research type
Research Study
Full title
Lp(a)CCELERATE: Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings
IRAS ID
357725
Contact name
Manish Saxena
Contact email
Sponsor organisation
Novartis Pharma AG
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
The European Society of Cardiology and the European Atherosclerosis Society recommend that everyone should have their lipoprotein(a), or Lp(a), levels tested at least once in their life. Lp(a) is a type of fat in the blood that can increase the risk of heart disease. However, even though this test is recommended, it is not commonly used in everyday medical practice.
This study will look at the impact of educational and implementation strategies developed in collaboration with the European Atherosclerosis Society (EAS). Each centre taking part in the study will implement a plan developed by experts to help increase Lp(a) testing. The plan will be customised based on local needs and challenges, which will be identified through a separate analysis.
The study will track how often Lp(a) tests are done over time in centres where testing is currently low or inconsistent. The goal is to see if the strategies help increase testing rates. The study will only use information that is already collected during normal patient care. This data will be taken from patients’ electronic health records.
In addition, healthcare professionals at the participating hospitals will be asked to complete a short survey. This will help us understand how practical and acceptable the strategies are from their point of view.
REC name
West of Scotland REC 3
REC reference
25/WS/0131
Date of REC Opinion
8 Aug 2025
REC opinion
Favourable Opinion